Transplantation
From the Journals
Recombinant vaccine cut herpes zoster rate in immunocompromised patients
In a randomized clinical trial of 1,846 adults who had undergone autologous HSCT, herpes zoster cases were seen in 49 and 136 individuals in the...
Conference Coverage
Survival exceeds 90% in transplant for SCD
FORT LAUDERDALE, FLA. — A pilot study has shown one-year overall survival rates exceeding 90% for bone marrow transplants in adults with severe...
News
FDA approves first drug for steroid-refractory acute GVHD
Ruxolitinib will be made available to appropriate patients immediately, according to Incyte.
Conference Coverage
More abnormal cells linked to poorer ASCT outcomes in MDS
NEWPORT BEACH, CALIF. – Patients with more than 60% cytogenetically abnormal cells at transplant had inferior overall survival and relapse-free...
Conference Coverage
Biomarker testing may transform treatment of acute GVHD
NEWPORT BEACH, CALIF. – Testing patient blood samples for two biomarkers may help guide early treatment of acute GVHD.
Conference Coverage
Monitoring, early intervention key to CAR T safety
GLASGOW – Dr. Loretta Nastoupil of the MD Anderson Cancer in Houston said that toxicity in CAR T-cell therapy “is something we don’t talk about as...
From the Journals
Quality of life decrement with salvage ASCT is short-lived
Salvage stem cell transplant in patients with multiple myeloma was linked to short-term, but not long-term, declines in quality of life, compared...
Video
ALF 2019 showcases evolving treatment of AML
NEWPORT BEACH, CALIF. – Dr. Martin Tallman discusses meeting presentations on the treatment of AML.
From the Journals
Infant survival rate after HCT remains flat
Survival rates remained largely unchanged from 2000-2014 for infants who underwent allogeneic hematopoietic cell...
Conference Coverage
MRD status at transplant predicts outcomes in ALL patients
HOUSTON – Acute lymphoblastic leukemia patients with measurable residual disease (MRD) negativity prior to...
Conference Coverage
Secondary AML in first remission predicts outcomes
HOUSTON – Secondary AML predicts outcomes after SCT in first complete remission, whereas factors such as age, cytogenetics, and performance status...